Tolerability  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
donkey ||| S:16 E:22 ||| NN
's  ||| S:22 E:25 ||| POS
milk  ||| S:25 E:30 ||| NN
in  ||| S:30 E:33 ||| IN
92  ||| S:33 E:36 ||| CD
highly-problematic  ||| S:36 E:55 ||| JJ
cow ||| S:55 E:58 ||| NN
's  ||| S:58 E:61 ||| POS
milk  ||| S:61 E:66 ||| NN
allergic  ||| S:66 E:75 ||| NN
children  ||| S:75 E:84 ||| NNS
Not  ||| S:84 E:88 ||| RB
exclusively  ||| S:88 E:100 ||| RB
breastfed  ||| S:100 E:110 ||| JJ
children  ||| S:110 E:119 ||| NNS
with  ||| S:119 E:124 ||| IN
cow ||| S:124 E:127 ||| NN
's  ||| S:127 E:130 ||| POS
milk  ||| S:130 E:135 ||| NN
allergy  ||| S:135 E:143 ||| NN
( ||| S:143 E:144 ||| -LRB-
CMA ||| S:144 E:147 ||| NNP
)  ||| S:147 E:149 ||| -RRB-
require  ||| S:149 E:157 ||| VBP
a  ||| S:157 E:159 ||| DT
formula  ||| S:159 E:167 ||| NN
or  ||| S:167 E:170 ||| CC
other  ||| S:170 E:176 ||| JJ
alternative  ||| S:176 E:188 ||| NN
food ||| S:188 E:192 ||| NN
,  ||| S:192 E:194 ||| ,
but  ||| S:194 E:198 ||| CC
past  ||| S:198 E:203 ||| JJ
and  ||| S:203 E:207 ||| CC
present  ||| S:207 E:215 ||| JJ
guidelines  ||| S:215 E:226 ||| NNS
differ  ||| S:226 E:233 ||| VBP
concerning  ||| S:233 E:244 ||| VBG
the  ||| S:244 E:248 ||| DT
best  ||| S:248 E:253 ||| JJS
choice ||| S:253 E:259 ||| NN
.  ||| S:259 E:261 ||| .
Our  ||| S:261 E:265 ||| PRP$
aim  ||| S:265 E:269 ||| NN
was  ||| S:269 E:273 ||| VBD
to  ||| S:273 E:276 ||| TO
investigate  ||| S:276 E:288 ||| VB
the  ||| S:288 E:292 ||| DT
clinical  ||| S:292 E:301 ||| JJ
tolerability ||| S:301 E:313 ||| NN
,  ||| S:313 E:315 ||| ,
palatability  ||| S:315 E:328 ||| NN
and  ||| S:328 E:332 ||| CC
nutritional  ||| S:332 E:344 ||| JJ
adequacy  ||| S:344 E:353 ||| NN
of  ||| S:353 E:356 ||| IN
donkey ||| S:356 E:362 ||| NN
's  ||| S:362 E:365 ||| POS
milk  ||| S:365 E:370 ||| NN
( ||| S:370 E:371 ||| -LRB-
DM ||| S:371 E:373 ||| NNP
)  ||| S:373 E:375 ||| -RRB-
in  ||| S:375 E:378 ||| IN
children  ||| S:378 E:387 ||| NNS
with  ||| S:387 E:392 ||| IN
proven  ||| S:392 E:399 ||| JJ
CMA ||| S:399 E:402 ||| NNP
.  ||| S:402 E:404 ||| .
It  ||| S:404 E:407 ||| PRP
was  ||| S:407 E:411 ||| VBD
important  ||| S:411 E:421 ||| JJ
to  ||| S:421 E:424 ||| TO
identify  ||| S:424 E:433 ||| VB
a  ||| S:433 E:435 ||| DT
CM  ||| S:435 E:438 ||| NNP
replacement  ||| S:438 E:450 ||| NN
for  ||| S:450 E:454 ||| IN
these  ||| S:454 E:460 ||| DT
children ||| S:460 E:468 ||| NNS
,  ||| S:468 E:470 ||| ,
highly  ||| S:470 E:477 ||| RB
problematic  ||| S:477 E:489 ||| JJ
from  ||| S:489 E:494 ||| IN
the  ||| S:494 E:498 ||| DT
feeding  ||| S:498 E:506 ||| JJ
standpoint ||| S:506 E:516 ||| NN
,  ||| S:516 E:518 ||| ,
in  ||| S:518 E:521 ||| IN
spite  ||| S:521 E:527 ||| NN
of  ||| S:527 E:530 ||| IN
their  ||| S:530 E:536 ||| PRP$
age ||| S:536 E:539 ||| NN
.  ||| S:539 E:541 ||| .
A  ||| S:541 E:543 ||| DT
prospective  ||| S:543 E:555 ||| JJ
study  ||| S:555 E:561 ||| NN
was  ||| S:561 E:565 ||| VBD
conducted  ||| S:565 E:575 ||| VBN
on  ||| S:575 E:578 ||| IN
92  ||| S:578 E:581 ||| CD
children  ||| S:581 E:590 ||| NNS
with  ||| S:590 E:595 ||| IN
CMA ||| S:595 E:598 ||| NNP
,  ||| S:598 E:600 ||| ,
diagnosed  ||| S:600 E:610 ||| VBN
through  ||| S:610 E:618 ||| IN
a  ||| S:618 E:620 ||| DT
CM  ||| S:620 E:623 ||| NNP
elimination  ||| S:623 E:635 ||| NN
diet ||| S:635 E:639 ||| NN
,  ||| S:639 E:641 ||| ,
followed  ||| S:641 E:650 ||| VBN
by  ||| S:650 E:653 ||| IN
double-blind ||| S:653 E:665 ||| NNP
,  ||| S:665 E:667 ||| ,
placebo-controlled  ||| S:667 E:686 ||| JJ
food  ||| S:686 E:691 ||| NN
challenge  ||| S:691 E:701 ||| NN
( ||| S:701 E:702 ||| -LRB-
DBPCFC ||| S:702 E:708 ||| NNP
)  ||| S:708 E:710 ||| -RRB-
unless  ||| S:710 E:717 ||| IN
contraindicated ||| S:717 E:732 ||| NN
.  ||| S:732 E:734 ||| .
Maternal  ||| S:734 E:743 ||| JJ
milk  ||| S:743 E:748 ||| NN
was  ||| S:748 E:752 ||| VBD
unavailable  ||| S:752 E:764 ||| JJ
and  ||| S:764 E:768 ||| CC
current  ||| S:768 E:776 ||| JJ
CM  ||| S:776 E:779 ||| NN
substitutes  ||| S:779 E:791 ||| NNS
could  ||| S:791 E:797 ||| MD
not  ||| S:797 E:801 ||| RB
be  ||| S:801 E:804 ||| VB
used ||| S:804 E:808 ||| VBN
.  ||| S:808 E:810 ||| .
Moreover ||| S:810 E:818 ||| RB
,  ||| S:818 E:820 ||| ,
89  ||| S:820 E:823 ||| CD
percent  ||| S:823 E:831 ||| NN
were  ||| S:831 E:836 ||| VBD
affected  ||| S:836 E:845 ||| VBN
by  ||| S:845 E:848 ||| IN
multiple  ||| S:848 E:857 ||| JJ
FA ||| S:857 E:859 ||| NNP
,  ||| S:859 E:861 ||| ,
and  ||| S:861 E:865 ||| CC
subjected  ||| S:865 E:875 ||| VBN
to  ||| S:875 E:878 ||| TO
very  ||| S:878 E:883 ||| RB
restricted  ||| S:883 E:894 ||| JJ
diets ||| S:894 E:899 ||| NN
.  ||| S:899 E:901 ||| .
Within  ||| S:901 E:908 ||| IN
3  ||| S:908 E:910 ||| CD
months  ||| S:910 E:917 ||| NNS
after  ||| S:917 E:923 ||| IN
the  ||| S:923 E:927 ||| DT
last  ||| S:927 E:932 ||| JJ
CM  ||| S:932 E:935 ||| NNP
challenge ||| S:935 E:944 ||| NN
,  ||| S:944 E:946 ||| ,
DBPCFC  ||| S:946 E:953 ||| NNP
for  ||| S:953 E:957 ||| IN
DM  ||| S:957 E:960 ||| NNP
was  ||| S:960 E:964 ||| VBD
performed ||| S:964 E:973 ||| VBN
.  ||| S:973 E:975 ||| .
CM  ||| S:975 E:978 ||| NNP
or  ||| S:978 E:981 ||| CC
DM  ||| S:981 E:984 ||| NNP
skin  ||| S:984 E:989 ||| NN
prick  ||| S:989 E:995 ||| NN
test  ||| S:995 E:1000 ||| NN
and  ||| S:1000 E:1004 ||| CC
sIgE  ||| S:1004 E:1009 ||| JJ
determination  ||| S:1009 E:1023 ||| NN
preceded  ||| S:1023 E:1032 ||| VBN
the  ||| S:1032 E:1036 ||| DT
CM  ||| S:1036 E:1039 ||| NNP
or  ||| S:1039 E:1042 ||| CC
DM  ||| S:1042 E:1045 ||| NNP
challenge ||| S:1045 E:1054 ||| NN
,  ||| S:1054 E:1056 ||| ,
respectively ||| S:1056 E:1068 ||| RB
.  ||| S:1068 E:1070 ||| .
Native  ||| S:1070 E:1077 ||| JJ
electrophoresis  ||| S:1077 E:1093 ||| NN
and  ||| S:1093 E:1097 ||| CC
immunoblotting  ||| S:1097 E:1112 ||| NNS
were  ||| S:1112 E:1117 ||| VBD
used  ||| S:1117 E:1122 ||| VBN
to  ||| S:1122 E:1125 ||| TO
identify  ||| S:1125 E:1134 ||| VB
CM  ||| S:1134 E:1137 ||| NNP
and  ||| S:1137 E:1141 ||| CC
DM  ||| S:1141 E:1144 ||| NNP
cross-reactive  ||| S:1144 E:1159 ||| JJ
proteins ||| S:1159 E:1167 ||| NNS
.  ||| S:1167 E:1169 ||| .
Z-scores  ||| S:1169 E:1178 ||| JJ
of  ||| S:1178 E:1181 ||| IN
weight  ||| S:1181 E:1188 ||| NN
and  ||| S:1188 E:1192 ||| CC
length ||| S:1192 E:1198 ||| NN
/ ||| S:1198 E:1199 ||| CD
stature  ||| S:1199 E:1207 ||| NN
for  ||| S:1207 E:1211 ||| IN
age  ||| S:1211 E:1215 ||| NN
were  ||| S:1215 E:1220 ||| VBD
calculated  ||| S:1220 E:1231 ||| VBN
at  ||| S:1231 E:1234 ||| IN
DM  ||| S:1234 E:1237 ||| NNP
food  ||| S:1237 E:1242 ||| NN
challenge  ||| S:1242 E:1252 ||| NN
( ||| S:1252 E:1253 ||| -LRB-
T0 ||| S:1253 E:1255 ||| NNP
)  ||| S:1255 E:1257 ||| -RRB-
and  ||| S:1257 E:1261 ||| CC
during  ||| S:1261 E:1268 ||| IN
DM  ||| S:1268 E:1271 ||| NNP
assumption.  ||| S:1271 E:1283 ||| CD
83  ||| S:1283 E:1286 ||| CD
children  ||| S:1286 E:1295 ||| NNS
( ||| S:1295 E:1296 ||| -LRB-
90.2  ||| S:1296 E:1301 ||| NNP
percent ||| S:1301 E:1308 ||| NN
)  ||| S:1308 E:1310 ||| -RRB-
liked  ||| S:1310 E:1316 ||| VBD
and  ||| S:1316 E:1320 ||| CC
tolerated  ||| S:1320 E:1330 ||| JJ
DM ||| S:1330 E:1332 ||| NNP
,  ||| S:1332 E:1334 ||| ,
at  ||| S:1334 E:1337 ||| IN
challenge  ||| S:1337 E:1347 ||| NN
and  ||| S:1347 E:1351 ||| CC
during  ||| S:1351 E:1358 ||| IN
follow-up ||| S:1358 E:1367 ||| NNP
,  ||| S:1367 E:1369 ||| ,
with  ||| S:1369 E:1374 ||| IN
increased  ||| S:1374 E:1384 ||| JJ
Z-score  ||| S:1384 E:1392 ||| NN
for  ||| S:1392 E:1396 ||| IN
weight  ||| S:1396 E:1403 ||| NN
and  ||| S:1403 E:1407 ||| CC
length ||| S:1407 E:1413 ||| NN
/ ||| S:1413 E:1414 ||| CD
stature  ||| S:1414 E:1422 ||| NN
and  ||| S:1422 E:1426 ||| CC
improved  ||| S:1426 E:1435 ||| JJ
nutritional  ||| S:1435 E:1447 ||| JJ
parameters ||| S:1447 E:1457 ||| NNS
.  ||| S:1457 E:1459 ||| .
Bovine  ||| S:1459 E:1466 ||| NNP
beta-lactoglobulin  ||| S:1466 E:1485 ||| NNP
was  ||| S:1485 E:1489 ||| VBD
identified  ||| S:1489 E:1500 ||| VBN
as  ||| S:1500 E:1503 ||| IN
the  ||| S:1503 E:1507 ||| DT
cross-reacting  ||| S:1507 E:1522 ||| JJ
protein  ||| S:1522 E:1530 ||| NN
among  ||| S:1530 E:1536 ||| IN
the  ||| S:1536 E:1540 ||| DT
DM  ||| S:1540 E:1543 ||| NNP
allergic  ||| S:1543 E:1552 ||| JJ
patients ||| S:1552 E:1560 ||| NNS
.  ||| S:1560 E:1562 ||| .
DM  ||| S:1562 E:1565 ||| NNP
was  ||| S:1565 E:1569 ||| VBD
found  ||| S:1569 E:1575 ||| VBN
to  ||| S:1575 E:1578 ||| TO
be  ||| S:1578 E:1581 ||| VB
a  ||| S:1581 E:1583 ||| DT
valid  ||| S:1583 E:1589 ||| JJ
alternative  ||| S:1589 E:1601 ||| NN
foodstuff ||| S:1601 E:1610 ||| NN
,  ||| S:1610 E:1612 ||| ,
in  ||| S:1612 E:1615 ||| IN
terms  ||| S:1615 E:1621 ||| NNS
of  ||| S:1621 E:1624 ||| IN
clinical  ||| S:1624 E:1633 ||| JJ
tolerability ||| S:1633 E:1645 ||| NN
,  ||| S:1645 E:1647 ||| ,
palatability  ||| S:1647 E:1660 ||| NN
and  ||| S:1660 E:1664 ||| CC
nutritional  ||| S:1664 E:1676 ||| JJ
adequacy ||| S:1676 E:1684 ||| NN
,  ||| S:1684 E:1686 ||| ,
in  ||| S:1686 E:1689 ||| IN
subjects  ||| S:1689 E:1698 ||| NNS
with  ||| S:1698 E:1703 ||| IN
CMA  ||| S:1703 E:1707 ||| NNP
who  ||| S:1707 E:1711 ||| WP
were  ||| S:1711 E:1716 ||| VBD
highly  ||| S:1716 E:1723 ||| RB
problematic  ||| S:1723 E:1735 ||| JJ
from  ||| S:1735 E:1740 ||| IN
the  ||| S:1740 E:1744 ||| DT
feeding  ||| S:1744 E:1752 ||| JJ
standpoint ||| S:1752 E:1762 ||| NN
.  ||| S:1762 E:1764 ||| .
